May 2, 2024Cancer Research

Abstract PO5-18-10: Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104)

View Full Paper

Ask AI

Bookmark

The trial aims to evaluate whether sentinel lymph node biopsy can be safely omitted in patients achieving complete response after neoadjuvant systemic therapy.
The primary endpoint is 3-year axillary recurrence-free survival with an expected rate of at least 98.5% across a target screened population of N=440 patients.
Prospective single-arm trial protocol may support surgical de-escalation in triple-negative breast cancer and HER2-positive breast cancer, with results pending.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Randomized trial evaluates omission of sentinel lymph node biopsy in responsive breast cancer, highlighting the potential to safely de-escalate surgery.

Cite This Study

Reimer et al. (2024) studied this question.

synapsesocial.com/papers/68e6be94b6db64358763e652 https://doi.org/10.1158/1538-7445.sabcs23-po5-18-10

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial evaluates omission of sentinel lymph node biopsy in responsive breast cancer, highlighting the potential to safely de-escalate surgery.

Abstract PO5-18-10: Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104)

Key Points

Discussion

Implication

Cite This Study

Abstract PO5-18-10: Omission of SLNB in triple-negative and HER2-positive breast cancer patients with radiologic and pathologic complete response in the breast after NAST: a single-arm, prospective surgical trial (EUBREAST-01 trial, GBG 104)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider